Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: A case study and review of the literature

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 10-16

  Camps, Simone M T ^a   Van Der Linden, Jan W M ^a   Li, Yi ^a   Kuijper, Ed J ^b   Van Dissel, Jaap T ^b   Verweij, Paul E ^a   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; AMINO ACID SUBSTITUTION; ANAMNESIS; ARTICLE; ASPERGILLOMA; ASPERGILLUS FUMIGATUS; CASE REPORT; CYP51A FUNGAL GENE; ESCHERICHIA COLI; FEMALE; FUNGAL GENE; FUNGUS CULTURE; FUNGUS ISOLATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; HUMAN; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; UROSEPSIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; GENOTYPE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION RATE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SPUTUM; TIME FACTORS; TRIAZOLES;

EID: 84455170146     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05088-11     Document Type: Article

References (34)

1. Alanio A, et al. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66:371-374.
2. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
3. Bellete B, et al. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48:197-200.
4. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
5. Chen J, Li H, Li R, Bu D, Wan Z. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37. (Pubitemid 40192611)
6. Dannaoui E, et al. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340. (Pubitemid 32229575)
7. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA. 1999. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European Research Group on Biotypes and Genotypes of Aspergillus fumigatus. J. Med. Microbiol. 48:1087-1093.
8. Denning DW, et al. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414. (Pubitemid 27437961)
9. Denning DW, et al. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368. (Pubitemid 27231443)
10. de Valk HA, et al. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J. Clin. Microbiol. 43:4112-4120.
11. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
12. Garcia-Effron G, et al. 2005. Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:2119-2121. (Pubitemid 40631636)
13. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49(Suppl 1):S90-S95.
14. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
15. Howard SJ, et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453. (Pubitemid 44740492)
16. Mann PA, et al. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47:577-581. (Pubitemid 36158085)
17. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
18. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
19. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438. (Pubitemid 32606215)
20. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750. (Pubitemid 38823458)
21. Nascimento AM, et al. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726. (Pubitemid 36548560)
22. Odds FC, Brown AJ, Gow NA. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279. (Pubitemid 36725017)
23. Pfaller MA, et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
24. Snelders E, et al. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75:4053-4057.
25. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54:2425-2430.
26. Snelders E, et al. 2011. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet. Biol. 48:1062-1070.
27. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
28. van der Linden JW, Arendrup MC, van der Lee HA. 2009. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Abstr. Trends Med. Mycol. 4:abstr O1.1.
29. van der Linden JW, et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
30. van der Linden JW, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
31. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE. 2007. Aspergillosis - and a misleading sensitivity result. Lancet 370:102.
32. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
33. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
34. Xiao L, et al. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574. (Pubitemid 38141718)